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ABSTRACT
Background. Western multicenter studies on distal pan-
createctomy with celiac axis resection (DP-CAR), also
known as the Appleby procedure, for locally advanced
pancreatic cancer are lacking. We aimed to study overall
survival, morbidity, mortality and the impact of preopera-
tive hepatic artery embolization (PHAE).
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Methods. Retrospective cohort study within the European-
African Hepato-Pancreato-Biliary-Association, on DP-
CAR between 1-1-2000 and 6-1-2016. Primary endpoint
was overall survival. Secondary endpoints were radicality
(R0-resection), 90-day mortality, major morbidity, and
pancreatic fistulae (grade B/C).
Results. We included 68 patients from 20 hospitals in 12
countries. Postoperatively, 53% of patients had R0-resec-
tion, 25% major morbidity, 21% an ISGPS grade B/C
pancreatic fistula, and 16% mortality. In total, 82%
received (neo-)adjuvant chemotherapy and median overall
survival in 62 patients with pancreatic ductal adenocarci-
noma patients was 18 months (CI 10–37). We observed no
impact of PHAE on ischemic complications.
Conclusions. DP-CAR combined with chemotherapy for
locally advanced pancreatic cancer is associated with
acceptable overall survival. The 90-day mortality is too
high and should be reduced. Future studies should inves-
tigate to what extent increasing surgical volume or better
patient selection can improve outcomes.
Locally advanced pancreatic cancer has a median sur-
vival ranging from 6 to 24 months, depending on the ability
to undergo both local and systemic treatment.1–3 In selected
cases, distal pancreatectomy with celiac axis resection (DP-
CAR) can lead to radical tumor removal in otherwise bor-
derline or unresectable disease.4–13 After celiac axis
resection, retrograde flow from the superior mesenteric
artery via the pancreatoduodenal arcades feeds the pancre-
atic head and the liver.14 In addition, some centers apply
preoperative hepatic artery embolization (PHAE) in an
attempt to improve collateral flow and reduce postoperative
(liver) ischemia, although its impact remains unclear.14,15
In a recent systematic review, we have shown that a
highly selected group of patients may benefit from DP-
CAR. In an analysis of 240 patients, overall survival was
18 months when DP-CAR was combined with (neo-)ad-
juvant chemotherapy at an acceptable 90-day mortality rate
of 3.5%.14 However, only relatively small studies (median
7 patients) of low-to-moderate quality could be included,
covering a 40-year period. The recent uptake of neoadju-
vant FOLFIRINOX (folinic acid, fluorouracil, irinotecan,
oxaliplatin) may eventually lead to higher down-staging
rates for pancreatic cancer, which could increase the
application of DP-CAR and improve survival.3,16
More recent reports, originating from the United States
and Japan, showed short-term mortality rates between 5
and 14% and median overall survival ranged from 17 to
40 months.17–20 However, still only single-center studies
exist, with the largest Western series consisting of 30
patients.17 The purpose of this pan-European study was to
assess overall survival and complications after DP-CAR,
including the effect of chemotherapy and PHAE, in a rel-
atively large, multicenter cohort.
METHODS
We performed a pan-European retrospective single-arm
cohort study on DP-CAR, among centers represented by
members of the European-African Hepato-Pancreato-Bil-
iary Association (E-AHPBA). The study protocol,
including an analysis framework, was initiated and
approved by the E-AHPBA research and scientific com-
mittee and made available online.21 We invited all
E-AHPBA members who had performed DP-CAR between
January 1, 2000 and May 31, 2016 to participate. The
institutional review board at the Academic Medical Center
Amsterdam waived the need for ethical review.
Patients and Data Collection
All participating centers completed an online survey
(GoogleTM Survey, Mountain View, CA) containing ques-
tions regarding standards of care and annual volumes for
pancreatic surgery. Each center appointed a local study
coordinator, responsible for questionnaire completion and
data collection. Subsequently, we retrieved all consecutive
patients who underwent DP-CAR for pancreatic cancer
within the study period. Patients were excluded in case of
non-pancreatic carcinoma diagnosis. Each center submitted
baseline (sex, age, BMI, ASA classification, surgical history,
and tumor characteristics), treatment (neoadjuvant therapy,
embolization, operative variables, adjuvant therapy), and
outcome data (morbidity, mortality, length of stay,
histopathology, and survival) anonymously using predefined
online case report forms (CRF). All data were collected and
analyzed by the central study coordinators (SK and JH).
Definitions
American Joint Committee on Cancer (AJCC) stage,
tumor size, and additional organ and vascular involvement
(other than pancreas, spleen, celiac axis, or splenic vessels)
were based on preoperative imaging (CT or MRI) and
postoperative pathology reports.22 Pre- and postoperative
chemotherapy and radiotherapy treatment was recorded,
including the use of FOLFIRINOX. PHAE was defined by
preoperative intraluminal catheter embolization of the
common hepatic artery. The intention to perform DP-CAR
versus intraoperative conversion from distal pancreatec-
tomy to DP-CAR was recorded in a separate variable
(intended vs. nonintended).
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Postoperative complications were scored as major
morbidity (grade 3a–4b) based on the Clavien-Dindo
classification of surgical complications.23 The definitions
of the International Study Group on Pancreatic Surgery
(ISGPS) were used to score postoperative pancreatic fis-
tula, delayed gastric emptying, and post-pancreatectomy
hemorrhage.24–26 Surgical site infection was defined using
the Center for Disease Control and Prevention (CDC)
definitions.27 Ischemic morbidity was defined as an
abdominal organ complication caused by surgery-related
ischemia.
Resection margins, including transection and circum-
ferential margins, were categorized according to the Royal
College of Pathologists definition and were classified as R0
(no residual, distance margin to tumor C 1 mm), R1
(residual tumor, distance margin to tumor \ 1 mm), and
R2 (residual tumor, macroscopically positive margin).28
Complications, readmissions, and mortality were all col-
lected up to 90 days postoperatively. Overall survival was
collected based on the last visit to the hospital, follow-up
phone calls, or national security registries depending on the
country of origin.
Outcomes
Primary outcome was overall survival. Secondary out-
comes were R0 resection margin, lymph node harvest,
postoperative mortality, morbidity (including ischemic
(liver) morbidity, postoperative pancreatic fistula, delayed
gastric emptying, post-pancreatectomy hemorrhage, organ
space (abdominal) infection), reinterventions, length of
hospital stay, and readmissions.
Statistical Analysis
All statistical analyses were performed using STATA
version 14.1 IC (StataCorp LP, College Station, TX).
Categorical data are presented as counts and proportions.
Continuous data are presented as both mean (standard
deviation) and median (interquartile range). All confidence
intervals (CI) are 95%, and alpha levels for significance are
\ 0.050. The Mann–Whitney U test and Fisher’s exact test
were used to compare continuous or categorical data,
respectively. We used Kaplan–Meier curves, stratified by
(neo-)adjuvant therapy regimen, to assess overall survival
after DP-CAR. We used the log-rank test to determine
significant differences in survival. To assess the impact of
annual pancreatic surgery case volume, we performed a
sensitivity analysis wherein we excluded all centers at or
below the median case volume for pancreatoduodenec-
tomy. We performed a univariate screen (P\ 0.20) and
multivariable analysis to assess potential factors associated
with 90-day mortality.
RESULTS
Of 35 initial responding hospitals, 20 hospitals across 12
European countries fulfilled the eligibility criteria and
included 72 patients undergoing DP-CAR between January
1, 2000 and May 31, 2016. After exclusion of three neu-
roendocrine tumors and one non-Hodgkin lymphoma, 68
patients with exocrine pancreatic cancer remained. All
participating hospitals were high-volume pancreatic cen-
ters (median of 70 pancreatoduodenectomies [interquartile
range (IQR) 31–88] per year). The median total case vol-
ume for DP-CAR was 3 (IQR 2–5). Of the participating
centers, 14 (70%) reported using DP-CAR in case of
intraoperatively detected celiac axis tumor involvement
and 3 (15%) reported routine use of PHAE.
Baseline and Treatment
Baseline characteristics are described in Table 1. Pre-
operatively, 15 (22%) patients received neoadjuvant
chemotherapy, 19 (28%) patients received neoadjuvant
chemoradiotherapy, and 15 (22%) patients received PHAE.
A minimally invasive DP-CAR was performed in 2 (2.9%)
patients. Vascular resection was performed in 18 (27%)
patients and adrenal gland resection in 15 (22%) patients.
A total of 9 (13%) patients underwent hepatic artery
reconstruction because of insufficient collateral flow via
the pancreatoduodenal arcade (Table 2). This included
aortae to hepatic artery (n = 6), superior mesenteric to
hepatic artery (n = 2), and gastroduodenal to hepatic artery
confluence (n = 1) bypasses.
Short-term Outcomes
R0 resection was achieved in 36 (55%) cases, with a
median lymph node harvest of 22 (IQR 16–30). After
surgery, 7 (10%) patients died within 30-days and 11
(16%) patients died within 90 days, all due to complica-
tions. Causes of death were related to gastric ischemia
(n = 3), liver ischemia (n = 2), post-pancreatectomy
hemorrhage (n = 2), pneumonia (n = 2), abdominal
infection (n = 1), and sepsis with multi-organ failure
(n = 1). Major morbidity occurred in 17 (25%) patients
and an ISGPF grade B/C fistula in 14 (21%) patients.
Median length of stay was 17 (IQR 11–27) days, with
readmission in 9 (14%) patients (Table 3). Between
patients who did (n = 15) and did not (n = 53) receive
PHAE, we found similar rates of liver ischemia (19% vs.
20%, P[ 0.99) and 90-day mortality (11% vs. 17%,
P[ 0.99). Reoperations were performed in 10 (14.7%)
patients. Reoperations were gastric (wedge) resection for
ischemia (n = 3), hepatic artery hemorrhage repair
(n = 2), re-do anastomosis for a hepatic confluence
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thrombus (n = 1) or hemorrhage (n = 1), gastrojejunos-
tomy for persistent delayed gastric emptying (n = 1), right
hemicolectomy for a perforation (n = 1), and embolec-
tomy of the right popliteal artery (n = 1).
Survival
Postoperative follow-up time ranged from 0 to
66 months, with a median of 10 months (IQR 4–19).
During the follow-up, 40 (59%) patients expired. This was
assessed by means of follow-up phone calls (49%), medical
record review (41%), or trough social security registry
review (10%). Of all patients, 56 (82%) received either
neoadjuvant or adjuvant chemotherapy, of which 12 (18%)
received at least one cycle of FOLFIRINOX (neoadjuvant
and adjuvant therapy characteristics; Supplement 1).
Among the 62 patients with pancreatic ductal adenocarci-
noma, Kaplan–Meier estimated median overall survival
was 18 months (CI 10–37) (Fig. 1). In this group, 1-year
survival was 60% (CI 46–72%) and 2-year survival was
45% (CI 29–59%).
Sensitivity and Subgroup Analysis
The sensitivity analysis indicated a nonsignificant trend
towards lower 90-day mortality in centers with an annual
pancreatoduodenectomy case volume above the median
(70 per year), total DP-CAR volume above 5, and proce-
dure year after 2008 (see Supplement 2). Among all 68
TABLE 1 Baseline characteristics
(N = 68)
Baseline
Female sex, no. (%) 32 (47.1)
Age, median (IQR), year 60 (52–67)
Mean (SD), year 58.9 (10.6)
Body-Mass-Index, median (IQR), kg/m2 24 (22–26.5)
Mean (SD), kg/m2 24.3 (3.6)
ASA-classification, no. (%)
ASA-1 12 (17.7)
ASA-2 50 (73.5)
ASA-3 6 (8.8)
Abdominal surgery history C 1, no. (%) 21 (32.8)
Preoperative tumor characteristics
Additional organ involvement*, no. (%)
Stomach 6 (8.8)
Liver 1 (1.5)
Kidney 3 (4.4)
Adrenal gland 5 (7.4)
Additional vascular involvement, no. (%)
Hepatic artery 8 (11.8)
Superior mesenteric artery 7 (10.3)
Portal vein 6 (8.8)
Superior mesenteric vein 9 (13.2)
Preoperative tumor size, median (IQR), mm 37 (30–50)
Mean (SD), mm 43 (33)
AJCC staging**, no. (%)
T-stage C 3 62 (95.4)
N-stage[ 0 20 (29.9)
M-stage[ 0 1 (1.5)
ASA American Society of Anesthesiologists
*Other than celiac axis, pancreas, or spleen
**Based on the AJCC criteria22
TABLE 2 Treatment characteristics
(N = 68)
Preoperative
Neoadjuvant treatment, no. (%)
Chemotherapy 15 (22.1)
Chemoradiotherapy 19 (27.9)
Preoperative hepatic artery embolization, no. (%) 15 (22.1)
Operative
Intent to perform DP-CAR 55 (80.9)
Operative time, median (IQR), min 328 (244–415)
Mean (SD), min 341 (124)
Additional organs resected*, no. (%)
Stomach 7 (10.3)
Liver 3 (4.4)
Kidney 3 (4.4)
Adrenal gland 15 (22.1)
Additional vessels resected, no. (%)
Right/left hepatic artery 1 (1.5)
Superior mesenteric artery 1 (1.5)
Portal vein 6 (8.8)
Superior mesenteric vein 10 (14.7)
Vascular reconstruction, no. (%)
Common hepatic artery 9 (13.2)
Superior mesenteric artery 1 (1.5)
Portal vein 6 (8.8)
Superior mesenteric vein 3 (4.4)
Estimated blood loss, median (IQR), mL 500 (350–1300)
Mean (SD), mL 922 (893)
Blood transfusion for bleeding (\ 72 h), no. (%) 20 (31.3)
Postoperative
Adjuvant treatment, no. (%)
Chemotherapy 41 (60.3)
Radiotherapy 2 (2.9)
Chemoradiotherapy 2 (2.9)
*Other than celiac axis, pancreas, or spleen
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patients, exploratory sub group analyses assessed neoad-
juvant and/or adjuvant chemotherapy/chemoradiation
versus no (neo-)adjuvant therapy (Supplement 3a), neoad-
juvant versus no neoadjuvant chemotherapy/
chemoradiation (Supplement 3b), and adjuvant versus no
adjuvant chemotherapy/chemoradiation (Supplement 3c).
However, the sample sizes became too low to achieve real
statistical solidity.
Predicting 90-day Mortality
Univariable analysis indicated potential predictors for
90-day mortality: mortality and male sex, additional vas-
cular involvement on CT/MRI, no neoadjuvant
chemotherapy, nonintended versus intended DP-CAR, and
an annual pancreatoduodenectomy volume above the
mean. However, except for male sex (odds ratio [OR] 9.45,
P = 0.04), none of these remained significant in multi-
variable analysis (Supplement 4).
DISCUSSION
In this largest Western series on DP-CAR to date, we
found a median overall survival of 18 months in 62
patients with pancreatic ductal adenocarcinoma involving
the celiac axis. We observed considerable 30-day (10%)
and 90-day (16%) mortality, without evidence indicating a
beneficial effect of PHAE on the need for arterial recon-
struction or ischemic complications. We observed a
nonsignificant trend for reduced risk of 90-day mortality
among high-volume centers.
These survival and morbidity outcomes are comparable
to prior evidence, although the 90-day mortality rate was
high. Overall survival after DP-CAR in the literature ran-
ges from median 17–20 months in two recent smaller
(n\ 20) series and one systematic review (n = 240) by
our group to median 31–35 months in two larger series
(n[ 25) from Sapporo and Pittsburgh.14,17–20 Overall
TABLE 3 Ninety-day outcomes after DP-CAR
(N = 68)
Outcomes
Mortality within 30 days, no. (%) 7 (10.3)
Mortality within 90 days, no. (%) 11 (16.4)
Complications within 90 days, no. (%)
Clavien-Dindo 3a–4b 17 (25)
Post-pancreatectomy hemorrhage*, no. (%) 6 (8.8)
Liver ischemia 12 (17.7)
Abdominal cavity infection, no. (%) 4 (5.9)
Pancreatic fistula grade B/C* no. (%) 14 (20.6)
Delayed gastric emptying grade B/C*, no. (%) 11 (17.5)
Reinterventions, no. (%)
Endoscopic intervention, no. (%) 1 (1.6)
Radiologic drainage, no. (%) 9 (14.5)
Reoperation, no. (%) 10 (14.7)
Gastric (wedge) resection for ischemia 3
Hemorrhage repair 2
Re-do vascular anastomosis 2
Gastrojejunostomy for DGE 1
Repair of metastatic colon perforation 1
Peripheral arterial embolectomy 1
Histopathology
Malignant etiology, no. (%)
PDAC 62 (91.2)
Invasive IPMN 3 (4.4)
Other malignant diagnosis 3 (4.4)
Tumor size, median (IQR), mm 40 (32–50)
Mean (SD), mm 44 (23)
Resection margin, no. (%)
R0 36 (54.6)
R1 28 (42.4)
R2 2 (3)
Lymph nodes harvested, median (IQR), no. 22 (16–29.5)
Median (SD), no. 25 (15)
Lymph node metastasis, no. (%) 45 (66.2)
Length of hospital say, median (IQR), days 16.5 (11–27)
Mean (SD), days 20 (14)
Unplanned readmission, no. (%) 9 (13.9)
Overall survival, median (CI), months 17 (10–33)
IPMN intraductal papillary mucinous neoplasm, PDAC pancreatic
ductal adenocarcinoma
*ISGPS definitions24–26
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FIG. 1 Survival curve after DP-CAR for pancreatic ductal adeno-
carcinoma. Kaplan–Meier survival estimate for 62 patients with
pancreatic ductal adenocarcinoma, excluding three patients with
invasive IPMN, and three patients with atypical pancreatic carcino-
mas. Median overall survival was 18 (CI 10–37) months. Vertical
bars indicate censored cases and yellow lines indicate the 95%
confidence interval (CI)
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survival for unresected patients with locally advanced
pancreatic cancer (AJCC Stage III) ranges from 7 months
in a large population-based study (n = 12,981) to
16–21 months with FOLFIRINOX in single-center studies
(n = 46–70).1,29,30 However, the existing evidence lacks
the necessary detailed information to study vascular
involvement.
Postoperative mortality rates in the literature range from
5% (4 of 80 patients) in-hospital mortality in the Sapporo
cohort to 14% (4 of 30 patients) 90-day mortality in the
Pittsburgh cohort.17,19 The latter included 11 patients who
underwent robot-assisted DP-CAR with 0% 90-day mor-
tality.17 Major morbidity rates in the published literature
range from 10% to more than 25%, but definitions are
heterogeneous.14,17–19 The R1 rate (43%) and lymph node
positive rate (66%) were comparable to the results from the
recent ESPAC-4 trial.31 Reports on PHAE in the literature
remain scarce, with routine use primarily reported by
Japanese studies.14
Although our study showed no evidence that PHAE
leads to fewer ischemic complications, no final conclusions
can be drawn. Apart from a lack of power to detect smaller
effects, PHAE may have prevented some aborted surgeries
when insufficient collateral flow was found before surgery.
Moreover, we were unable to study the potentially bene-
ficial effects of embolization of all three celiac axis
branches versus the common hepatic artery alone, as
described by Cesaretti and colleagues.32 We also could not
assess the impact of preservation or reconstruction of the
left gastric artery using the middle colic artery on gastric
ischemia, as described by Okada and colleagues.33 Such
techniques can only be adequately studied via prospective
registries, such as the Arterial Network, including patients
in whom intended DP-CAR was aborted because of
insufficient collateral blood flow.34 Conversely, we found
that in 13 (20%) patients, DP-CAR was performed as an
extension to distal pancreatectomy in which initially no
vascular resection was planned.
In contrast to our expectations, we did not find a sig-
nificant association between neoadjuvant chemotherapy
and improved survival after DP-CAR. However, the recent
report from Pittsburgh (n = 30), in which the authors
describe a 96% neoadjuvant therapy rate and a 35-month
median overall survival, suggests an important role for
neoadjuvant treatment.17 As the authors state, neoadjuvant
therapy can be given to downstage the tumor but more
importantly to enable detection and treatment of occult
micrometastatic disease before committing patients to DP-
CAR.17 Now that FOLFIRINOX treatment has become the
new standard of care, the benefit of neoadjuvant
chemotherapy may increase further.17,18,20 The assessment
of vascular involvement on imaging after FOLFIRINOX in
pancreatic cancer is unreliable.35 In our study, seven
patients appeared to have SMA involvement, whereas only
one patient required a SMA resection.
This study had several limitations. First, we were unable
to include a control group, because a comparable sample of
unresected patients with celiac axis involvement was
unavailable. Second, selection or reporting bias may have
occurred through self-selection by centers with favorable
experience with DP-CAR. We aimed to limit this effect by
giving anonymity to participating centers. Third, although
we tried to collect the biggest Western sample to date, our
sample size remains limited. Fourth, study design and data
collection commenced before the release of the 8th edition
of the AJCC staging criteria; therefore, all staging defini-
tions are according to the 7th edition.22,36 Finally, even
though only (very) high-volume centers were included, the
number of DP-CAR procedures per center was very low.
We can only speculate that outcomes may improve with
higher volumes.
In conclusion, this study showed that DP-CAR with
(neo-)adjuvant treatment (82% of the cases) is associated
with an acceptable median overall survival of 18 months.
Future efforts should be designed to reduce the 90-day
mortality to acceptable levels through better patient
selection or centralization of treatment.
ACKNOWLEDGEMENT The authors acknowledge the office of
the European-African Hepato-Pancreato-Biliary Association for sup-
porting this study. Collaborators of the E-AHPBA DP-CAR study
group: Panagis Lykoudis, MD, at NHS London, Thilo H. Hackert,
MD, at Heidelberg University, and Zeeshan Ateeb at the Karolinska
University Hospital.
FUNDING No specific funding obtained.
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
REFERENCES
1. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th
edition AJCC pancreatic cancer staging system: report from the
National Cancer Database110. Cancer. 2007;110(4):738–44.
https://doi.org/10.1002/cncr.22852
2. Rombouts SJ, Mungroop TH, Heilmann MN, et al. FOLFIR-
INOX in locally advanced and metastatic pancreatic cancer: a
single centre cohort study. J Cancer. 2016;7(13):1861–6. https://
doi.org/10.7150/jca.16279.
3. Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally
advanced pancreatic cancer: a systematic review and patient-level
meta-analysis. Lancet Oncol. 2016;2045(16):1–10. https://doi.
org/10.1016/s1470-2045(16)00172-8.
Outcomes After DP-CAR for PDAC 1445
4. Appleby LH. The coeliac axis in the expansion of the operation
for gastric carcinoma. Cancer. 1953;6(4):704–7.
5. Nimura Y, Hattory T, Miura K, Nakajima N, Hibi M. Our
experience of resection of carcinoma of the body and tail of the
pancreas by Appleby’s procedure. Operation.
1976;15(30):885–9.
6. Katz MH, Marsh R, Herman JM, et al. Borderline
resectable pancreatic cancer: need for standardization and meth-
ods for optimal clinical trial design. Ann Surg Oncol.
2013;20(8):2787–95. https://doi.org/10.1245/s10434-013-2886-9.
7. Tempero MA, Malafa MP, Behrman SW, et al. Pancreatic ade-
nocarcinoma, version 2.2014. J Natl Compr Cancer Netw.
2014;12:1083–93.
8. Bockhorn M, Uzunoglu FG, Adham M, et al.: Borderline
resectable pancreatic cancer: a consensus statement by the
International Study Group of Pancreatic Surgery (ISGPS). Sur-
gery. 2014;155(6):977–88. https://doi.org/10.1016/j.surg.2014.
02.001.
9. Fishman EK, Al-Hawary M, Francis IR, Merchant NB, Sahani D,
Tamm E. NCCN clinical practice guidelines in oncology: pan-
creatic adenocarcinoma. version 2.2015. Natl Compr Cancer
Netw. 2015. https://doi.org/10.1007/174_2014_977.
10. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William
Traverso L, Linehan DC. Pretreatment assessment of
resectable and borderline resectable pancreatic cancer: expert
consensus statement. Ann Surg Oncol. 2009;16(7):1727–33.
https://doi.org/10.1245/s10434-009-0408-6.
11. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline
resectable pancreatic cancer: definitions, management, and role
of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035–46.
https://doi.org/10.1245/aso.2006.08.011.
12. Landelijke-werkgroep-Gastrointestinale-TUMOREN. Pancreatic
cancer: Dutch guidelines, version 2.0. Integraal Kankercentrum
Nederland; 2011. http://www.oncoline.nl/pancreascarcinoom.
Accessed 5 Jan 2015.
13. Seufferlein T, Bachet JB, Van Cutsem E, Rougier P. Pancreatic
adenocarcinoma: ESMO-ESDO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl.
7):vii33–40. https://doi.org/10.1093/annonc/mds224.
14. Klompmaker S, De Rooij T, Korteweg JJ, et al. Systematic
review of outcomes after distal pancreatectomy with coeliac axis
resection for locally advanced pancreatic cancer. Br J Surg.
2016;103(8):941–9. https://doi.org/10.1002/bjs.10148.
15. Kondo S, Katoh H, Shimizu T, et al. Preoperative embolization of
the common hepatic artery in preparation for radical pancreate-
ctomy for pancreas body cancer. Hepatogastroenterology.
2000;47(35):1447–9.
16. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus
gemcitabine for metastatic pancreatic cancer. N Engl J Med.
2011;364(19):1817–25. https://doi.org/10.1056/nejmoa1011923.
17. Ocuin LM, Miller-Ocuin JL, Novak SM, et al. Robotic and open
distal pancreatectomy with celiac axis resection for locally
advanced pancreatic body tumors: a single institutional assess-
ment of perioperative outcomes and survival. HPB.
2016;18(10):835–42. https://doi.org/10.1016/j.hpb.2016.05.003.
18. Peters NA, Javed AA, Cameron JL, et al. Modified Appleby
procedure for pancreatic adenocarcinoma: does improved
neoadjuvant therapy warrant such an aggressive approach? Ann
Surg Oncol. 2016;23(11):3757–64. https://doi.org/10.1245/
s10434-016-5303-3.
19. Nakamura T, Hirano S, Noji T, et al. Distal pancreatectomy with
en bloc celiac axis resection (modified Appleby procedure) for
locally advanced pancreatic body cancer: a single-center review
of 80 consecutive patients. Ann Surg Oncol. 2016;23(Suppl
5):969–75. https://doi.org/10.1245/s10434-016-5493-8.
20. Sugiura T, Okamura Y, Ito T, Yamamoto Y, Uesaka K. Surgical
indications of distal pancreatectomy with celiac axis resection for
pancreatic body/tail cancer. World J Surg. 2016;41(1):258–66.
https://doi.org/10.1007/s00268-016-3670-3.
21. Klompmaker S, van Hilst J, Gerritsen1 S, et al. Pan-European
E-AHPBA series of distal pancreatectomy with celiac axis
resection (DP-CAR; Appleby) for cancer. 2016. http://www.e-
mips.org/wp-content/uploads/sites/3/2016/12/Protocol-
EAHPBA-Appleby-cohort-2016.6.3.pdf. Accessed 3 June 2016.
22. Compton C, Byrd D, Garcia-Aguilar J, Kurtzman S, Olawaiye A,
Washington M. Exocrine and endocrine pancreas. In: Edge S,
Byrd D, Compton C, Fritz A, Greene F, Trotti A, editors. AJCC
Cancer Staging Manual. 7th ed. New York: Springer; 2010,
p. 241–9. https://doi.org/10.1007/978-1-4614-2080-4.
23. Dindo D, Demartines N, Clavien P-A. Classification of surgical
complications: a new proposal with evaluation in a cohort of
6336 patients and results of a survey. Ann Surg.
2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.
54934.ae.
24. Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying
(DGE) after pancreatic surgery: a suggested definition by the
International Study Group of Pancreatic Surgery (ISGPS). Sur-
gery. 2007;142(5):761–8. https://doi.org/10.1016/j.surg.2007.05.
005.
25. Wente MN, Veit JA, Bassi C, Dervenis C. Postpancreatectomy
hemorrhage (PPH)—an International Study Group of Pancreatic
Surgery (ISGPS) definition. Surgery. 2007;142(1):20–5. https://
doi.org/10.1016/j.surg.2007.02.001.
26. Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of
the International Study Group (ISGPS) definition and grading of
postoperative pancreatic fistula: 11 years after. Surg.
2017;161(3):584–91. https://doi.org/10.1016/j.surg.2016.11.014.
27. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR.
Guideline for prevention of surgical site infection, 1999. Centers
for Disease Control and Prevention (CDC) Hospital Infection
Control Practices Advisory Committee. Am J Infect Control.
1999;27(2):97–132. https://doi.org/10.1016/s0196-
6553(99)70088-x. quiz 133-4; discussion 96.
28. The Royal College of Pathologists. Standards and minimum
datasets for reporting cancers minimum dataset for the
histopathological reporting of pancreatic, ampulla of Vater and
bile duct carcinoma. London: The Royal College of Pathologists.
2002;261035.
29. Sadot E, Doussot A, O’Reilly EM, et al. FOLFIRINOX induction
therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol.
2015;22(11):3512–21. https://doi.org/10.1245/s10434-015-4647-
4.
30. Conroy T, Paillot B, Franc¸ois E, et al. Irinotecan plus oxaliplatin
and leucovorin-modulated fluorouracil in advanced pancreatic
cancer—a Groupe Tumeurs Digestives of the Fe´de´ration Natio-
nale des Centres de Lutte Contre le Cancer study. J Clin Oncol.
2005;23(6):1228–36. https://doi.org/10.1200/jco.2005.06.050.
31. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of
adjuvant gemcitabine and capecitabine with gemcitabine
monotherapy in patients with resected pancreatic cancer
(ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Lancet. 2017;6736(16):1-14. https://doi.org/10.1016/s0140-
6736(16)32409-6.
32. Cesaretti M, Abdel-Rehim M, Barbier L, Dokmak S, Hammel P,
Sauvanet A. Modified Appleby procedure for borderline resect-
able/locally advanced distal pancreatic adenocarcinoma: a major
procedure for selected patients. J Visc Surg. 2016. https://doi.org/
10.1016/j.jviscsurg.2015.11.014.
33. Okada K, Kawai M, Tani M, et al. Preservation of the left gastric
artery on the basis of anatomical features in patients undergoing
distal pancreatectomy with celiac axis en-bloc resection (DP-
1446 S. Klompmaker et al.
CAR). World J Surg. 2014;38(11):2980–5. https://doi.org/10.
1007/s00268-014-2702-0.
34. Fusai GK, Pereira S, Valente R, Ravikumar R, Lykoudis P. The
arterial study network. 2015. https://www.thearterialstudy.net.
Accessed 10 Sept 2015.
35. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and
surgical implications of neoadjuvant treatment with FOLFIR-
INOX for locally advanced and borderline resectable pancreatic
cancer. Ann Surg. 2015;261(1):12–7. https://doi.org/10.1097/sla.
0000000000000867.
36. Amin MB, Edge S, Greene F, Byrd DR, Robert K. Brookland,
Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, Milburn Jessup J, Brierley JD, Gaspar LE, Richard
L, Schi LRM. AJCC cancer staging manual. 8th ed. New York:
Springer; 2017
Outcomes After DP-CAR for PDAC 1447
